Liver/Biliary Disorders News

SAN DIEGO — Combination therapy with peginterferon alfa-2b and nucleos(t)ide analogues resulted in significantly higher hepatitis B surface antigen loss vs. monotherapy in children with HBV, especially among those aged younger than 7 years.

SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated steatotic liver disease after liver transplantation, noted a presenter at The Liver Meeting.

SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data.

SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks, according to late-breaking data.

SAN DIEGO — Patients with decompensated alcohol-associated cirrhosis and ascites taking naltrexone had lower risk for all-cause mortality and liver disease complications, including acute kidney injury and spontaneous bacterial peritonitis.

Children with obesity have increased risk for type 2 diabetes if they are diagnosed with metabolic dysfunction-associated steatotic liver disease, according to findings published in Diabetes Care.

SAN DIEGO — Treatment with combination tobevibart and elebsiran led to hepatitis B surface antigen loss among 39% of patients with chronic HBV and low baseline HBsAg, which rose to 46% by adding pegylated interferon-alfa, data showed.

SAN DIEGO — Liver stiffness measurements may help predict the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease, as well as identify those in need of surveillance, according to data.

SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting.